To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

This study has been completed.
Sponsor:
Information provided by:
Repros Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00706719
First received: June 25, 2008
Last updated: June 29, 2011
Last verified: June 2011
Results First Received: August 25, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Infertility in Men
Secondary Hypogonadism
Interventions: Drug: Androxal (enclomiphene citrate)
Drug: topical testosterone gel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Testim (Topical Testosterone) 1% Testim gel applied once daily
Androxal no Washout 25 mg Androxal capsules once daily in men who have not previously washed out topical testosterone
Androxal With Wash Out 25 mg capules once daily in men who have previously had a 3 month wash out of topical testosterone

Participant Flow:   Overall Study
    Testim (Topical Testosterone)     Androxal no Washout     Androxal With Wash Out  
STARTED     5     7     5  
COMPLETED     5     6     1  
NOT COMPLETED     0     1     4  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Group A Testim 1% Testim gel
Group B Androxal no Wash Out 25 mg Androxal 1 capusule per day in men who have not previously washed out topical testosterone for 3 months
Androxal Wash Out 25 mg 1 capsule per day in men who have undergone a 3 month wash out period of topical testosterone
Total Total of all reporting groups

Baseline Measures
    Group A Testim     Group B Androxal no Wash Out     Androxal Wash Out     Total  
Number of Participants  
[units: participants]
  5     7     5     17  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     5     7     5     17  
>=65 years     0     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  54.4  ± 4.88     48.9  ± 8.99     56.4  ± 23.8     52.7  ± 7.72  
Gender  
[units: participants]
       
Female     0     0     0     0  
Male     5     7     5     17  
Region of Enrollment  
[units: participants]
       
United States     5     7     5     17  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Sperm Concentration Baseline   [ Time Frame: baseline ]

2.  Primary:   Mean Sperm Concentration 3 Months   [ Time Frame: 3 months ]

3.  Primary:   Mean Sperm Concentraion 6 Months   [ Time Frame: 6 months ]

4.  Primary:   Mean Total Sperm Count Basline   [ Time Frame: baseline ]

5.  Primary:   Mean Total Sperm Count 3 Months   [ Time Frame: 3 months ]

6.  Primary:   Mean Total Sperm Count 6 Months   [ Time Frame: 6 months ]

7.  Primary:   Mean Semen Volume Baseline   [ Time Frame: baseline ]

8.  Primary:   Mean Semen Volume 3 Months   [ Time Frame: 3 months ]

9.  Primary:   Mean Semen Volume 6 Months   [ Time Frame: 6 months ]

10.  Secondary:   Mean Follicle Stimulating Hormone(FSH) and Leutinizing Hormone(LH) Levels From Baseline to 3-months in Men Treated With Androxal® Versus Testim   [ Time Frame: baseline, 3 months ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Ronald Wiehle, PhD
Organization: Repros Therapeutics, Inc
phone: 281.719.3406
e-mail: rwiehle@reprosrx.com


No publications provided


Responsible Party: Ronald Wiehle, PhD, Repros Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT00706719     History of Changes
Other Study ID Numbers: ZA-201
Study First Received: June 25, 2008
Results First Received: August 25, 2010
Last Updated: June 29, 2011
Health Authority: United States: Food and Drug Administration